Cadila Pharmaceuticals Introduces Innovative Iron Injection Treatment

Cadila Pharmaceuticals has recently launched a new product called Redshot FCM, a novel iron injection to treat Iron Deficiency anemia. The infusion, fortified with the advanced Ferric Carboxymallose formulation, has been specifically designed for adult and pediatric patients over one year of age who suffer from oral iron intolerance.

This new product has an exemplary safety profile and delivers effective amounts of iron, promoting the acceleration of hemoglobin levels and efficiently replenishing depleted iron stores.

According to Cadila Pharmaceuticals, the intravenous delivery of iron facilitates the utilization of high doses in a single administration, offering heightened tolerance with minimal to zero risk of anaphylaxis. Dr. Rajiv I. Modi, the Chairman and Managing Director of Cadila Pharmaceuticals, expressed his excitement for the product, stating that it exemplifies the company's commitment to pharmaceutical excellence, contribution to the safe motherhood initiative, and correction of iron deficiency anemia.

Anemia is a condition that is often inadequately managed and goes unnoticed, characterized by impaired physical activity, general weakness, lethargy, and fatigue. This condition is particularly prevalent among the elderly, pregnant women, and cancer patients. Cadila Pharmaceuticals has launched a novel iron injection to address iron deficiency anemia. The product, available as Redshot FCM  fortified with the advanced Ferric Carboxymallose formulation, is designed for adults and pediatric patients over one year, especially those with oral iron intolerance, according to an official release on Tuesday.

“Redshot Injection is an intravenous iron preparation that delivers effective amounts of iron and boasts an exemplary safety profile. With superior tolerability and minimal to zero risk of anaphylaxis, Redshot accelerates the improvement of hemoglobin levels and efficiently replenishes depleted iron stores. Offering heightened tolerance, the intravenous delivery of iron facilitates the utilization of high doses in a single administration,” the company added.

Dr. Rajiv I. Modi, Chairman and Managing Director of Cadila Pharmaceuticals, said, “This innovation exemplifies our commitment to pharmaceutical excellence, contribution to the safe motherhood initiative, and correction of iron deficiency anemia. It offers superior tolerance and presents a transformative approach to replenishing iron stores rapidly and efficiently.”

Anaemia, characterized by impaired physical activity, general weakness, lethargy, and fatigue, often goes unnoticed and is inadequately managed, particularly in pregnancy, the elderly population, and cancer patients.